Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? by Wahiba Elhag (5245547)

“…Postoperatively, there was a significant and sustained weight reduction, amounting to a mean decrease of 9 kg/m² in BMI at year 9 and associated excess weight loss between 59%_year 1 and 46%_year 9. …”

Tranexamic Acid Application in Facial Aesthetic Surgery: An Umbrella Review by Mohamed Badie Ahmed (10223510)

“…While in the case of septorhinoplasty, 3 studies revealed that TXA use decreased BLV. Moreover, in the case of rhytidectomy, 3 out of 6 systematic reviews showed reduction in BLV, while 2 reported reductions in DOS. …”

Does standalone phacoemulsification lower intraocular pressure in glaucomatous eyes? A systematic review and meta-analysis by Osama Hussein (21301202)

“…In ACG patients, medication use decreased by 67.13% at 12 months and 51.58% at 24 months (<i>p</i> < 0.001 for both), while in OAG patients, the reduction was 45.52% at 12 months and 50.19% at 24 months (<i>p</i> < 0.001). …”

The cost-benefit associated with the maturity of the Antimicrobial Stewardship Program versus prematurity in Heart Hospital of Hamad Medical Corporation in Qatar by Dina Abushanab (10696501)

“…With M-ASP, cost of hospital tests use ‘decreased’ by QAR 1,149 per 100-patient beds per year, cost of ASP personnel ‘decreased’ by QAR 125 per 100-patient beds with the M-ASP, cost of drug use ‘increased’ by QAR 176,848 per 100-patient beds, cost of resistance and hospitalization ‘increased’ by QAR 216,279 per 100-patient beds per year. …”

A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country by Nancy Zaghloul (14147865)

“…</p><h3>Results</h3><p dir="ltr">SGLT2is prescriptions increased from 1045 (2.13%) in 2017 to 8375 (12.39%) in 2020, while sulfonylureas prescriptions declined from 10,436 (21.25%) to 9158 (13.55%) during the same period. Metformin use decreased from 23,926 (48.71%) in 2017 to 30,886 (45.70%) in 2020. …”

Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Diseas... by Parkes J Kendrick (9714851)

“…Although global age-standardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: –1·21% [–1·26 to –1·16]), similar progress was not observed for chewing tobacco (0·46% [0·13 to 0·79]). …”